Tildren

Tiludronate bisphosphonate for management of navicular syndrome and other osseous conditions in horses. Bisphosphonate (tiludronate disodium). Mechanism: nitrogen-containing bisphosphonate — binds hydroxyapatite in bone → internalized by osteoclasts → inhibits farnesyl pyrophosphate synthase (mevalonate pathway) → impairs osteoclast function and survival → reduced bone resorption and remodeling. Also inhibits subchondral bone nociceptor activity (analgesic mechanism). Single slow IV infusion. Key information Tiludronate bisphosphonate. Equine only. IV infusion over 60 min. Monitor renal function. Do not administer rapidly (hypocalcemia risk). Wear gloves.

IV infusion (horses): dilute in 1 L 0.9% NaCl; infuse over 60 min via jugular catheter. Ensure horse is well hydrated before administration. Single-dose treatment. Monitor during and after infusion. Store at room temperature; protect from light. If a dose is missed This medication is administered by a veterinarian or veterinary staff in a clinical setting. Missed doses are managed by your veterinary team — contact your veterinarian to reschedule.

GI: colic, reflux, anorexia (horses — transient, within first 24 hrs). Renal: azotemia (risk with dehydration — ensure adequate hydration before infusion). Hypocalcemia (bisphosphonate — monitor ionized calcium). Injection site reactions. Ataxia (rare, high doses). Uveitis (rare).

For animals Horses only. Ensure adequate hydration for 24 hrs before and after infusion. Monitor renal function, hydration status, and urine output. Monitor for colic, diarrhea, or adverse GI signs in first 24 hrs. Avoid concurrent nephrotoxic drugs. Not approved for use in food-producing animals. Do not repeat for at least 6 months. For people handling this medication Administered by veterinary professionals only. No specific human precautions for caregivers beyond normal hygiene.

Contact your veterinarian. Tiludronate overdose causes hypocalcemia and kidney damage. Administered by veterinary staff.